Real-World study tracks IBD Patients' choice of vedolizumab injection vs. infusion

NCT ID NCT04989907

First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 18 times

Summary

This study watched 92 adults with Crohn's disease or ulcerative colitis as they received vedolizumab either as an IV infusion or a shot under the skin. Researchers did not assign treatments—they simply recorded what patients and their doctors decided, and how long patients stayed on each option. The goal was to understand real-world treatment patterns, not to test if the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bauchzentrum INSELSPITAL, Universitatsspital Bern

    Bern, 3010, Switzerland

  • Clarunis AG

    Basel, 4002, Switzerland

  • Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum

    Bern, 3012, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Universitatsspital Zurich

    Zurich, 8091, Switzerland

  • Zentrum fur Gastroenterologie und Hepatologie AG

    Zurich, 8048, Switzerland

Conditions

Explore the condition pages connected to this study.